Regulatory writing for immunology
Long-term safety follow-up, opportunistic-infection reporting, immunogenicity, and biologic CMC complexity. Asthra carries the narrative forward with consistency across reporting periods.
Immunology development runs long. Biologic programs collect long-term safety data across multiple reporting periods. Opportunistic-infection screening and reporting have specific conventions. Immunogenicity (anti-drug antibodies, neutralising antibodies) is a first-class safety topic. And the CMC load for biologics — glycosylation, higher-order structure, cell-line characterisation — dwarfs what a small-molecule program carries. Asthra drafts against all of it, keeping the narrative consistent from cycle to cycle.
Regulatory pressure points in immunology
Where Asthra changes the shape of the work
Long-term safety follow-up across many reporting periods
Biologics in immunology accumulate years of safety data. PSUR cycles reuse earlier content extensively — but only where the evidence genuinely has not changed. Asthra handles that reuse explicitly, with a section-level mode (reuse, revise, rewrite) and honest provenance preservation.
Opportunistic-infection surveillance has standing reporting conventions
Hepatitis screening, TB screening, herpes reactivation, progressive multifocal leukoencephalopathy — each has specific capture and reporting patterns. Asthra keeps those patterns stable across CSRs and periodic reports.
Immunogenicity reporting links clinical and analytical data
ADA and nAb narratives require drawing from specialised bioanalytical data and linking it to clinical outcomes. Asthra keeps the two sides cited separately and tied together in the narrative, so the reviewer can follow the link both ways.
Biologic CMC is genuinely complex
Module 3 for a biologic spans cell-line characterisation, process consistency, higher-order structure, glycosylation, and stability across formulation changes. Asthra consolidates these from the source documents with full provenance per specification.
Biosimilars and comparative CSRs
For biosimilar programs, comparative narrative against a reference product runs through the CSR, PSUR, and CMC. Asthra keeps the comparison framing consistent across the three, with citations back to both the reference product data and the biosimilar data.
Documents Asthra drafts for this area
The regulated documents you produce most often
CSR (ICH E3)
Full CSR first draft with long-term safety handling, immunogenicity integration, and biosimilar-comparative narrative where relevant.
Learn more →PSUR / PBRER / DSUR
Periodic reports that carry forward long-running safety surveillance with per-section reuse / revise / rewrite modes.
Learn more →CMC (eCTD Module 3)
Biologic Module 3 consolidation covering cell-line characterisation, process consistency, comparability, and stability.
Learn more →Regulatory context we keep in mind
Not a substitute for your regulatory strategy — just the background Asthra is aware of
ICH Q5 series — biological product quality
Governs cell-line characterisation, process consistency, and viral safety for biologic programs. Asthra's Module 3 template reflects this ordering.
ICH Q6B — specifications for biotechnological products
Specifications narrative for biologics draws from analytical method validation and stability data. Asthra keeps the citation chain intact from method to specification to release result.
FDA and EMA biosimilar guidance
Biosimilar comparability narrative has its own conventions. Asthra's templates are configurable to the comparative structure these guidances expect.
Immunogenicity assessment guidance (FDA and EMA)
ADA and nAb narrative expectations are well-defined. Asthra aligns the immunogenicity subsection of the CSR to these expectations by default.
Immunology programs run the longest, produce the most biologic CMC content, and generate the most complex periodic reports in the industry. Asthra takes the cross-cycle consistency load off the writer's desk. The clinical interpretation, benefit-risk, and immunogenicity judgement stay with the team that understands the biology.
See Asthra on a immunology document
Bring a real source file — protocol, PSUR, CER, or Module 3 — and we'll run Asthra against it in a live demo.
Last updated: 16 April 2026